A review of evidence supports expanding the high-risk criteria for administration of RSV immunization in infants and children 8 through 19 months of age entering their second RSV season.
Abstract
This policy statement updates recommendations of the American Academy of Pediatrics (AAP) for the use of respiratory syncytial virus (RSV) immunization for the prevention of lower respiratory tract infection (LRTI) caused by RSV in infants and children. The AAP recommends RSV immunization for all infants under 8 months of age born during or entering their first RSV season, unless the infant has documented protection from vaccination of their pregnant parent; and for infants and children 8 through 19 months of age who are at high risk of severe RSV disease and entering their second RSV season. A review of evidence supports expanding the high-risk criteria for administration of RSV immunization in infants and children 8 through 19 months of age entering their second RSV season. A discussion of the evidence supporting the AAP recommendations and additional details on infants and children included in the expanded recommendations are in the accompanying technical report (https://doi.org/10.1542/peds.2026-079049).
This technical report accompanies the American Academy of Pediatrics (AAP) policy statement (https://doi.org/10.1542/peds.2026-079047) and recommendations for respiratory syncytial virus (RSV) immunization during the 2026-2027 RSV season. The rationale is presented for recommending immunization of all infants younger t...
This policy statement updates the recommendations of the American Academy of Pediatrics (AAP) for the use of COVID-19 vaccines in the prevention of severe COVID-19 in children. A review of evidence supporting these recommendations is in the accompanying technical report (https://doi.org/10.1542/peds.2026-079046). These...
The rationale is presented for recommending vaccination in all infants and children 6 through 23 months of age, children 6 months through 18 years of age who are moderately or severely immunocompromised, and children 2 through 18 years of age in certain additional risk groups, including those at high risk of severe COV...
Objective: To assess the prevalence of asthma in a cohort of preterm infants, comparing
those who received prophylaxis with palivizumab, a monoclonal antibody against
respiratory syncytial virus (RSV), with those who did not. That is relevant because RSV
infection has been linked to recurrent wheezing and asthma in chi...
Mariana Bueno Manini, Natali Caroline da Silva, Gabriela Do Amaral Gurgel Cruz et al.· Respiratory Research & C...· 0 citations
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections in young children. In 2019, RSV was estimated to cause approximately 33 million acute lower respiratory infections, 3.6 million hospitalisations and more than 101,000 deaths among children under five years of age, with more than...
RSV and bronchiolitis are major causes of hospitalizations and death among infants. The RSVpreF vaccine was approved and released in 2023 for pregnant women to prevent severe RSV in infants during their first RSV season. This is the first prenatal vaccine recommended since the COVID-19 vaccine was approved. Howev...
Corinne R. Thornton, S. Bhumbra· Journal of the Pediatric Inf...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.